Understanding and treating systemic JIA in children
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study looks at children with systemic juvenile idiopathic arthritis (sJIA), a type of arthritis that causes joint swelling, fever, and rash. The goal is to learn more about the disease and how it's treated to improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be under 18 years old.
- Your child must have been diagnosed with systemic JIA.
- Your child can be newly diagnosed or already being treated.
- Your child cannot have other rheumatic or autoimmune diseases.
- Your child cannot have infections, cancer, or other conditions that mimic sJIA.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a bone marrow transplant (using donor cells) to treat severe systemic juvenile idiopathic arthritis (sJIA) that has not responded to other treatments. The goal is to reset the immune system to stop the disease and its complications, like lung problems or recurrent macrophage activation syndrome.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This Phase 3 study tests whether children with early juvenile idiopathic arthritis do better by starting with one treatment approach and adjusting (stepping up or stepping down) based on how their arthritis responds. It may help find the safest, most effective long-term plan for controlling symptoms with fewer side effects.
This study tests different arthritis medications given in sequence for children and young adults with polyarticular JIA who did not get enough relief from a first TNF inhibitor. It aims to find which next treatment works best and is safe.
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
Hear when a new Systemic Juvenile Idiopathic Arthritis (sJIA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.